MX2022005812A - Metodos de tratamiento de enfermedades y trastornos relacionados con desmetilasa 1 especifica de lisina con inhibidores de desmetilasa 1 especifica de lisina. - Google Patents

Metodos de tratamiento de enfermedades y trastornos relacionados con desmetilasa 1 especifica de lisina con inhibidores de desmetilasa 1 especifica de lisina.

Info

Publication number
MX2022005812A
MX2022005812A MX2022005812A MX2022005812A MX2022005812A MX 2022005812 A MX2022005812 A MX 2022005812A MX 2022005812 A MX2022005812 A MX 2022005812A MX 2022005812 A MX2022005812 A MX 2022005812A MX 2022005812 A MX2022005812 A MX 2022005812A
Authority
MX
Mexico
Prior art keywords
lsd1
treating
disorders
methods
related diseases
Prior art date
Application number
MX2022005812A
Other languages
English (en)
Inventor
Takumitsu Machida
Hiroko Hitotsumachi
Masaki Yamada
Harold Keer
Aram Oganesian
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of MX2022005812A publication Critical patent/MX2022005812A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/04—Monocyclic monocarboxylic acids
    • C07C63/06—Benzoic acid
    • C07C63/08—Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Un método para tratar una enfermedad o trastorno relacionado con LSD1 en un paciente que lo necesita, comprendiendo el método administrar una cantidad eficaz de 4-[5-[(3S)-3-aminopirrolidin-1- carbonil]-2-[2-fluoro-4-(2-hidroxi-2-metil-propil)fenil]fenil]-2- fluoro-benzonitrilo o una de sus sales al paciente en un programa de administración que comprende la dosificación diaria durante una o dos semanas, seguida de un período de descanso de una semana.
MX2022005812A 2019-11-13 2020-11-13 Metodos de tratamiento de enfermedades y trastornos relacionados con desmetilasa 1 especifica de lisina con inhibidores de desmetilasa 1 especifica de lisina. MX2022005812A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962934923P 2019-11-13 2019-11-13
PCT/JP2020/042410 WO2021095840A1 (en) 2019-11-13 2020-11-13 METHODS OF TREATING LSD1-RELATED DISEASES and Disorders WITH LSD1 INHIBITORS

Publications (1)

Publication Number Publication Date
MX2022005812A true MX2022005812A (es) 2022-08-16

Family

ID=75912767

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2022005812A MX2022005812A (es) 2019-11-13 2020-11-13 Metodos de tratamiento de enfermedades y trastornos relacionados con desmetilasa 1 especifica de lisina con inhibidores de desmetilasa 1 especifica de lisina.
MX2022005811A MX2022005811A (es) 2019-11-13 2020-11-13 Sal novedosa de compuesto de terfenilo.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022005811A MX2022005811A (es) 2019-11-13 2020-11-13 Sal novedosa de compuesto de terfenilo.

Country Status (11)

Country Link
US (2) US20220411368A1 (es)
EP (2) EP4058018A4 (es)
JP (2) JP7379680B2 (es)
KR (2) KR20220113390A (es)
CN (2) CN114728899B (es)
AU (2) AU2020382214B2 (es)
BR (2) BR112022009221A2 (es)
CA (2) CA3158442A1 (es)
MX (2) MX2022005812A (es)
TW (2) TW202128616A (es)
WO (2) WO2021095840A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4319732A1 (en) 2021-04-08 2024-02-14 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors for treating myeloid cancers
WO2022240886A1 (en) * 2021-05-11 2022-11-17 Astex Pharmaceuticals, Inc. Solid forms of salts of 4-[5-[(3s)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-ethylpropyl)phenyl]phenyl]-2-fluoro-benzonitrile
AU2022355189A1 (en) * 2021-09-30 2024-04-11 Astex Pharmaceuticals, Inc. Combinatory therapy for cancer using biphenyl compound and immune checkpoint molecule regulator
WO2023076302A1 (en) 2021-10-26 2023-05-04 Astex Pharmaceuticals, Inc. Process for preparing a benzoate salt of a 1-(3-aminopyrrolidine-1-carbonyl)-3,4-diphenylbenzene compound
WO2023217784A1 (en) 2022-05-09 2023-11-16 Oryzon Genomics, S.A. Methods of treating nf1-mutant tumors using lsd1 inhibitors
WO2023217758A1 (en) 2022-05-09 2023-11-16 Oryzon Genomics, S.A. Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102452803B1 (ko) * 2012-05-09 2022-10-07 캔텍스 파마슈티칼즈, 인크. 골수억제의 치료
MA43318A (fr) * 2015-11-27 2018-10-03 Taiho Pharmaceutical Co Ltd Nouveau composé de biphényle ou un sel de celui-ci
RU2765153C2 (ru) * 2017-05-26 2022-01-26 Тайхо Фармасьютикал Ко., Лтд. Усилитель противоопухолевого эффекта с применением нового соединения бифенила
JP6843979B2 (ja) * 2017-05-26 2021-03-17 大鵬薬品工業株式会社 新規なビフェニル化合物又はその塩
AU2018276611B2 (en) * 2017-05-31 2022-01-06 Taiho Pharmaceutical Co., Ltd. Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1
PL3644999T3 (pl) * 2017-06-30 2023-05-08 Celgene Corporation Kompozycje i sposoby zastosowania 2-(4-chlorofenylo)-n-((2-(2,6-dioksopiperydyn-3-ylo)-1-oksoizoindolin-5-ylo)metylo)-2,2-difluoroacetamidu

Also Published As

Publication number Publication date
TW202128616A (zh) 2021-08-01
AU2020382379A1 (en) 2022-05-05
BR112022008020A2 (pt) 2022-07-12
EP4058151A1 (en) 2022-09-21
TW202128617A (zh) 2021-08-01
EP4058018A1 (en) 2022-09-21
KR20220101145A (ko) 2022-07-19
AU2020382379B2 (en) 2024-03-28
EP4058151A4 (en) 2023-10-25
AU2020382214A1 (en) 2022-04-21
CN114828844A (zh) 2022-07-29
KR20220113390A (ko) 2022-08-12
EP4058018A4 (en) 2023-06-21
JP7379680B2 (ja) 2023-11-14
US20220411368A1 (en) 2022-12-29
CA3158442A1 (en) 2021-05-20
CN114728899A (zh) 2022-07-08
CN114728899B (zh) 2023-12-05
AU2020382214B2 (en) 2023-07-06
JP7492002B2 (ja) 2024-05-28
JP2023501627A (ja) 2023-01-18
BR112022009221A2 (pt) 2022-07-26
US20220387384A1 (en) 2022-12-08
WO2021095835A1 (en) 2021-05-20
CA3157404A1 (en) 2021-05-20
JP2022550374A (ja) 2022-12-01
WO2021095840A1 (en) 2021-05-20
MX2022005811A (es) 2022-06-08

Similar Documents

Publication Publication Date Title
MX2022005812A (es) Metodos de tratamiento de enfermedades y trastornos relacionados con desmetilasa 1 especifica de lisina con inhibidores de desmetilasa 1 especifica de lisina.
EA202090955A1 (ru) Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови
JP2018111728A5 (es)
SA519402076B1 (ar) مشتقات فينيل جديدة
BR112014010803A2 (pt) método de tratamento
MX2017010858A (es) Composicion para el tratamiento de enfermedades relacionadas con la interleucina 6.
JOP20200156A1 (ar) إيسكيتامين لعلاج الاكتئاب
BR112015008399A2 (pt) composições para modular a expressão de c90rf72
MX2019010994A (es) Metodos para tratar enfermedades y trastornos mediados por el complemento.
MX365206B (es) Metodo para el tratamiento de la enfermedad de parkinson.
BR112019006228A2 (pt) tratamento de câncer de próstata
MX2021011110A (es) Tratamiento de ataque de angioedema hereditario con dosis reducida de anticuerpos que se unen a calicreína plasmática humana.
EA201892190A1 (ru) Лечение псориаза антителом к ил-12 и/или ил-23 с возрастанием интервала между введениями дозы
MX2014002471A (es) Combinaciones sinergicas de los inhibidores de p13k y mek.
NZ598722A (en) Methods for treating psoriasis
MX2023000187A (es) Dosificacion de vibegron para el tratamiento de vejiga sobreactiva.
EP4279127A3 (en) Growth differentiation factor 15 as biomarker for metformin
BR112015012497A2 (pt) combinações farmacêuticas
MX2020007222A (es) Metodos para el tratamiento de afecciones inflamatorias de la piel.
MX2013008654A (es) Combinaciones.
MX2018005298A (es) Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa.
PH12020551527A1 (en) Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders
UA115063U (xx) Спосіб лікування собак із больовим синдромом при панкреатиті
AR102494A1 (es) Métodos para tratar enfermedades oculares
MX2021002761A (es) Metodos para tratar la pancreatitis.